MedTrace Logo

Effect of ACE Genotype on Cardiovascular Rehabilitation

NCT02845063 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-08-16

No results posted yet for this study

Summary

The study aims to systematically investigate the interaction between training modality, ACE genotype and disease in heart patients whom complete a cardiovascular rehabilitation program. This is carried out with the goal to improve the benefit of cardiovascular rehabilitation for the patient by maximising adjustments in muscle structure and function with the intervention. A population of healthy individuals will be recruited who will carry out the same training program, in order to compare the training effects respective to the general population.

Conditions

Interventions

BEHAVIORAL

concentric cardiovascular training

Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.

BEHAVIORAL

eccentric cardiovascular training

Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.

GENETIC

ACE genotyping

Subjects will be genotyped for the ACE-I/D gene polymorphism.

Sponsors & Collaborators

  • University of Zurich

    collaborator OTHER

  • Balgrist University Hospital

    lead OTHER

Principal Investigators

  • Walter O Frey, MD · Balgrist University Hospital, Move>med, Swiss Olympic Center, Zurich, Switzerland

  • Christian M Schmied, MD · Cardiology, University Hospital Zurich, Zurich, Switzerland

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-01
Primary Completion
2019-01-01
Completion
2020-01-01

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02845063 on ClinicalTrials.gov